ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.
On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
http://www.imclone.com
Details
Employees
380
Founded
9184
Location
United States
Phone
+13172762000
Industry
biotechnology research
Keywords
monoclonal antibodies
biopharmaceutical company
Browse SuperAGI Directories
AI Native CRM for Unified Sales, Support & Marketing
Accelerate growth and streamline your entire stack with AI CRM Platform